Search Results
Your search for early matches 10131 pages
Showing 7051 - 7100Raising Awareness of Medullary Thyroid Carcinoma
I’m used to having bumps and cysts pop up on my body, so when I felt a lump on the front of my throat, just below my Adam’s apple, I brushed it off. But when it was still there 6 months later, I became concerned and decided to see an ear, nose, and throat specialist. He performed a fine-needle...
Radiation: Myths, Facts, Dangers and Benefits
For many, the word “radiation” conjures up images of mushroom clouds and the nightmarish nuclear disaster at Chernobyl. It also brings to mind those pesky dental x-rays and lifesaving cancer treatments. However, to most people, radiation is a mysterious invisible power to be feared and embraced...
Immunotherapy Could Be the Wave of the Future, but Problems and Challenges Cannot Be Ignored
Immunotherapy is on its way. A few agents have already been approved: ipilimumab (Yervoy) in 2011 for melanoma; nivolumab (Opdivo) in 2015 for non–small cell lung cancer (NSCLC) and then later that year for renal cell carcinoma; and pembrolizumab (Keytruda) for NSCLC. In addition, many clinical...
Supportive Care in the Older Adult With Cancer: What You Need to Know
The median age of patients at the first diagnosis of cancer in the United States is 65 years, and the majority of patients with cancer are older adults.1 As we have learned from previous articles in this series, older patients with cancer require more complex care. Older adults are more likely to...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young people in the United States—and millions worldwide—from life-threatening cancers, ASCO said April 11 in a policy statement. Published by Bailey et al in the Journal of Clinical Oncology,1 the...
Leena Gandhi, MD, PhD, Named Director of Thoracic Medical Oncology at NYU Langone’s Perlmutter Cancer Center
New York University (NYU) Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as Director of Thoracic Medical Oncology at its Laura and Isaac Perlmutter Cancer Center. In this new role, Dr. Gandhi will be tasked with building a robust program in lung...
Adjuvant Trastuzumab May Be Insufficiently Used in Older Women With Breast Cancer
Reeder-Hayes et al found that adjuvant trastuzumab (Herceptin) may be underused in older women with early-stage HER2-positive breast cancer and reported their study results in the Journal of Clinical Oncology. Adjuvant trastuzumab also was used less often in black women than in white women. Rates...
Blue Ribbon Panel to Help Guide National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer ...
Expert Point of View: Thierry Facon, MD
Thierry Facon, MD, of Lille University Hospital in France, told The ASCO Post that he believes elotuzumab (Empliciti) works better with an immunomodulatory drug than with bortezomib (Velcade), at least according to the results of these two studies. “I think what’s most impressive is the ELOQUENT-2 ...
Pembrolizumab Looks Promising in Multiple Myeloma
Monoclonal antibodies targeting the programmed cell death protein (PD-1) receptor look promising in multiple myeloma, according to early reports presented at the 2015 ASH Annual Meeting and Exposition. Early signs of activity in heavily pretreated patients may indicate that, as in solid tumors,...
Active Surveillance Has Become Standard Care for Men With Low-Risk Localized Prostate Cancer
Active surveillance has been increasingly adopted as a standard approach for men with Gleason score ≤ 6 localized prostate cancer, with major guidelines and consensus statements encouraging this approach,1 including a recently published guideline from Cancer Care Ontario (CCO),2 and endorsement of...
DigniCap Scalp-Cooling System Now Available for Women With Breast Cancer at 10 U.S. Cancer Treatment Centers
Dignitana Inc. recently announced that the DigniCap scalp cooling system, which was cleared by the U.S. Food and Drug Administration (FDA) in December 2015 to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now available at 10 cancer treatment...
ASCO Endorses Cancer Care Ontario Guideline on Active Surveillance for Management of Localized Prostate Cancer
As reported by Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed, with qualifications, the 2015 Cancer Care Ontario (CCO) guideline on active surveillance for management of localized prostate cancer....
In Ductal Carcinoma in Situ, Benefit of Wider Margins Tied to Radiation Use
The relationship between margin width and risk of recurrence after breast-conserving surgery for ductal carcinoma in situ depends on the use of radiation, according to a surgical oncologist who sought to determine the optimal margin width in these patients.1 “Positive margins are associated with an ...
AACR 2016: Certain Oral Bacteria May Be Associated With Increased Pancreatic Cancer Risk
The presence of two species of bacteria linked to periodontal disease in the mouths of healthy individuals was associated with an increased risk of subsequently developing pancreatic cancer, according to research presented by Fan et al at the 2016 AACR Annual Meeting (Abstract 4350). ...
Interim FDG-PET Response-Adapted Therapy May Be of Benefit in Hodgkin Lymphoma
In a phase II US Intergroup trial (Southwest Oncology Group S0816) reported in the Journal of Clinical Oncology, Press et al found that early interim fluorodeoxyglucose positron-emission tomography (FDG-PET) to guide response-adapted therapy resulted in progression-free survival substantially...
Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma
Although high-dose chemotherapy plus autologous transplantation has been a standard of care in the treatment of younger patients with newly diagnosed multiple myeloma, the advent of effective novel agents for the cancer over the past 15 years has raised the question of whether transplantation, with ...
Novel Strategies Emerging for Triple-Negative Breast Cancer
Compelling hypotheses are emerging about the mechanisms driving triple-negative breast cancer, and they are driving drug development in this area, according to Joyce O’Shaughnessy, MD, Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center. She is also Medical...
AACR 2016: Palbociclib Shows Antiproliferative Activity in Early-Stage Breast Cancer
The molecularly targeted therapeutic palbociclib (Ibrance) was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who received no prior therapy, according to data from a phase II clinical trial presented by Arnedos et al at the 2016 AACR...
AACR 2016: MammaPrint Genetic Test Can Reduce Use of Adjuvant Chemotherapy Among Early-Stage Breast Cancer Patients
Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biologic criteria, the MammaPrint genetic test identified a large group of patients for whom 5-year distant metastasis–free survival was equally good whether or not they ...
AACR 2016: RAF-Targeted Therapeutic BGB-283 Shows Early Promise Against Tumors With BRAF and RAS Mutations
The new investigational anticancer therapeutic BGB-283, which targets the RAF family of proteins, was safe, tolerable, and showed signs of clinical activity in patients who had a range of types of cancer with mutations in BRAF, KRAS, and NRAS, according to results from a phase I clinical trial...
Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer
Hypofractionated radiotherapy was not inferior to conventional radiotherapy in terms of disease-free survival among men with low-risk prostate cancer, according to the results of the phase III NRG Oncology RTOG 0415 trial reported in the Journal of Clinical Oncology by Lee et al. However, it was...
Higher EZH2 and Ki67 Expression May Be Associated With Aggressive Basal Cell Carcinoma
In a study reported in a research letter in JAMA Oncology, Rao et al found that high expression of EZH2 and Ki67 was associated with more-aggressive basal cell carcinoma.EZH2 is a histone methyltransferase of the polycomb repressive complex 2. EZH2 overexpression or gain of function mutations has...
Greatest Benefit of Adjuvant Exemestane Seen in Premenopausal Women at Higher Risk of Breast Cancer Recurrence
In an analysis of the SOFT and TEXT trials reported in the Journal of Clinical Oncology, Regan et al found that the greatest benefit of adjuvant exemestane in reducing breast cancer recurrence was among women with the highest risk of recurrence on the basis of clinicopathologic characteristics....
ELCC 2016: Immunotherapy With Live Bacterium Improves Response Rate in Malignant Pleural Mesothelioma
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and a 59% response rate in patients with malignant pleural mesothelioma, according to the results of a phase Ib trial presented by Jahan et al April 14 (Abstract 208O_PR) at the European Lung...
ILC 2016: High Rate of Cancer Recurrence Found in Patients With Hepatitis C Taking Direct-Acting Antiviral Treatments
Data from a new study show that patients with hepatitis C virus (HCV) taking direct-acting antiviral treatments who have previously been diagnosed with hepatocellular carcinoma had a high rate of redeveloping their illness. The large retrospective cohort study (Abstract LBP506), presented by...
Use of 21-Gene Recurrence Score Assay in Early-Stage Breast Cancer
The 21-gene recurrence score (RS) assay score was strongly associated with recommendation for adjuvant chemotherapy in patients with early-stage breast cancer, reported Jasem et al in the Journal of Clinical Oncology. Black women and patients treated in community facilities were more likely to...
FDA Accepts Supplemental Biologics License Application for Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer, Grants Priority Review
Merck today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), a monoclonal antibody and anti–programmed cell death 1 (PD-1) therapy, for the treatment of...
Preclinical Studies Show Many Androgen-Deprivation Therapies May Suppress Adaptive Immune Responses
Prostate cancer patients and their doctors may want to think twice about the best timing for chemotherapy or radiation therapy in conjunction with a common nonsurgical treatment, based on international research findings led by UT Southwestern Medical Center investigators. Researchers using mouse...
Adding Ovarian Function Suppression to Tamoxifen Worsened Some Patient-Reported Outcomes in Premenopausal Women With Early Breast Cancer
Ribi et al reported in the Journal of Clinical Oncology that addition of ovarian function suppression to tamoxifen resulted in greater endocrine and sexual function symptoms among premenopausal patients with early breast cancer in the Suppression of Ovarian Function Trial (SOFT). The SOFT study...
In Early Brain Radiation Recovery Studies, Cranial Grafting of Stem Cell–Derived Therapy Improves Cognition and Reduces Neuropathology
While stem cells have shown promise for treating brain regions damaged by cancer radiation treatments, University of California, Irvine (UCI) researchers have found that microscopic vesicles isolated from these cells provide similar benefits without some of the risks associated with stem cells....
Dutch Study Indicates Low Locoregional Recurrence in Young Women With Early-Stage Breast Cancer
Aalders et al found relatively low rates of locoregional recurrence among young (< 35 years) Dutch women undergoing surgery for unilateral invasive breast cancer between 2003 and 2008. Recurrence rates varied somewhat by biologic subtype, according to these findings reported in the Journal of...
Study Finds Decreased Use of Primary Breast-Conserving Surgery for Women in New York State
In a study reported in JAMA Surgery, Isaacs et al found that use of primary breast-conserving surgery for early-stage breast cancer has declined somewhat in recent years in New York State, most steeply among younger women. In addition, 90-day reoperation rates have declined and are lower for...
Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older
A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was published in the Journal of Oncology Practice. The corresponding author...
Most Patients With Melanoma Had Few Nevi, None Atypical
Although nevi are considered among the strongest risk factors for melanoma, most patients with melanoma had few total nevi and no atypical nevi, according to an analysis of 566 patients with invasive cutaneous melanoma. “Three notable findings emerged from this case study,” Alan C. Geller, MPH, RN, ...
10 Bladder Cancer Projects Awarded Research Grants by Johns Hopkins Greenberg Bladder Cancer Institute
The Johns Hopkins Greenberg Bladder Cancer Institute is a collaborative initiative of the Johns Hopkins Kimmel Cancer Center, the Brady Urological Institute, the Bloomberg School of Public Health, and the School of Medicine. It aims to develop new clinical strategies for combating bladder cancer...
Sadik Esener, PhD, Selected to Lead OHSU’s Large-Scale Early Cancer Detection Initiative
Sadik Esener, PhD, has been recruited to the Oregon Health & Science University (OHSU) Knight Cancer Institute to lead the first large-scale early cancer detection program of its kind. Dr. Esener will be the Director of the Institute’s Center for Early Detection Research and has been awarded...
Things May Not Be What They Seem: Are Old Cancer Treatment Theories New Again?
The adage “you can’t judge a book by its cover,” is true, but authors still need to be aware of the importance of first impressions. The title of science writer Travis Christofferson’s book Tripping Over the Truth: The Return of the Metabolic Theory of Cancer Illuminates a New and Hopeful Path to ...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Israel
The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Israel. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For...
Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer
The oncology research team at HonorHealth Research Institute in Scottsdale, Arizona, is spearheading a phase Ib/II trial that is demonstrating promising results with a novel regimen in patients with advanced pancreatic cancer. “The patients we are treating have advanced adenocarcinoma of the...
Decreased PSA Screening and Decreased Diagnosis of Early-Stage Prostate Cancer
Recent data indicate that the rate of prostate-specific antigen (PSA) screening and the rate of diagnosis of early-stage prostate cancer have decreased since a 2012 U.S. Preventive Services Task Force (USPSTF) statement (released in October 2011) gave a grade D recommendation against PSA...
Selected Abstracts From 2015 ASH Annual Meeting: Part 4
Here is the final installment of selected abstracts from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. For other selected abstracts...
Sarah L. Blair, MD, on Early-Stage Breast Cancer in Older Women: Surgical Management
Sarah L. Blair, MD, of UC San Diego Moores Cancer Center, discusses surgical resection of breast cancer, which has the best chance of cure and is better than hormonal treatment alone, even in patients over age 80.
Providing Perspective on Pressing Economic Issues Facing Cancer Care—Now and in the Future
CANCERSCAPE, the 2016 Annual Meeting of the Association of Community Cancer Centers (ACCC), provided a forum for about 300 attendees to gain insight into the complexities of oncology treatment, where “clinical advances, policy mandates, and value-based payment reform intersect.” Of particular...
Understanding and Preparing for MACRA
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed in April 2015, introducing comprehensive changes to how Medicare pays physicians for services. As the policies passed in MACRA are rolled out over the coming years, they will profoundly impact reimbursement and care...
Update of ASCEND-1 Trial Shows Ceritinib Highly Active in ALK-Rearranged NSCLC, Including Intracranial Disease
Updated results of the phase I ASCEND-1 trial, reported by Kim et al in The Lancet Oncology, indicate that the ALK inhibitor ceritinib (Zykadia) produced high response rates in advanced ALK-rearranged non–small cell lung cancer (NSCLC), including intracranial disease, in both patients with and...
NCI Announces Blue Ribbon Panel to Help Guide Vice President Biden’s National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National...
Breast Cancer Vaccines Moving Forward at a Fast Clip
Vaccines for both secondary and primary prevention of breast cancer are showing potential in clinical trials, according to Elizabeth A. Mittendorf, MD, PhD, who is leading much of the vaccine research at the University of Texas MD Anderson Cancer Center, Houston. Vaccine platforms being explored...
Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO
Clifford A. Hudis, MD, FACP, Chief of the Breast Medicine Service, Vice President for Government Relations, and Chief Advocacy Officer at Memorial Sloan Kettering Cancer Center (MSKCC), and Professor of Medicine at Weill Cornell Medical College, has been named the next Chief Executive Officer...
Douglas E. Wood, MD, on Lung Cancer Screening: Status and Patient Selection
Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
